Sodium ozagrel and atorvastatin for type 2 diabetes patients with lacunar cerebral infarction

doi:10.4239/wjd.v12.i12.2096

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 12

This Article

Peer-Review Report of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9642)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

404

WORD

HTML

3481

Figures (1-2)

521

Tables (1-2)

1056

Sum=5558

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

466

Download

1371

Sum=1837

Publishing Process of This Article

Item

Count

Browse

610

Download

1643

Sum=2253

Dec 15, 2021 (publication date) through Mar 1, 2026

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Retrospective Study

World J Diabetes. Dec 15, 2021; 12(12): 2096-2106
Published online Dec 15, 2021. doi: 10.4239/wjd.v12.i12.2096

Sodium ozagrel and atorvastatin for type 2 diabetes patients with lacunar cerebral infarction

You Yu, Lin Wang, Xu Zhu, Ya-Fei Liu, Hai-Ying Ma

You Yu, Lin Wang, Xu Zhu, Ya-Fei Liu, Hai-Ying Ma, Department of Pharmacy, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, Liaoning Province, China

Author contributions: Yu Y and Ma HY designed the research study; Wang L and Yu Y performed the research; Zhu X, Liu YF and Ma HY analyzed the data and wrote the manuscript; and all authors have read and approve the final manuscript.

Institutional review board statement: The study was reviewed and approved by The Fourth Affiliated Hospital of China Medical University Institutional Review Board.

Informed consent statement: All study participants provided informed written consent prior to study enrollment.

Conflict-of-interest statement: None.

Data sharing statement: No additional data are available.

Corresponding author: Hai-Ying Ma, MHSc, Chief Pharmacist, Department of Pharmacy, The Fourth Affiliated Hospital of China Medical University, No. 4 Chongshan Road, Huanggu District, Shenyang 110032, Liaoning Province, China. mhy2021888@163.com

Received: September 2, 2021
Peer-review started: September 2, 2021
First decision: October 3, 2021
Revised: October 15, 2021
Accepted: December 10, 2021
Article in press: December 10, 2021
Published online: December 15, 2021
Processing time: 104 Days and 22.6 Hours

ARTICLE HIGHLIGHTS

Research background

Type 2 diabetes is a common metabolic disease that is often complicated by abnormal lipid metabolism.

Research motivation

As an antiplatelet drug and thromboxane A inhibitor, sodium ozagrel is widely used to treat ischemic cerebrovascular diseases.

Research objectives

We want to observe the effects of sodium ozagrel combined with atorvastatin on high-mobility group protein B1 (HMGB1) and high-sensitivity-C reactive protein (hs-CRP) in patients with type 2 diabetes mellitus and lacunar infarction.

Research methods

Eighty-two patients with type 2 diabetes mellitus and lacunar infarction treated were categorized into two groups according to the method of treatment (41 patients in each group).

Research results

After treatment, the blood glucose indexes; blood lipid indexes; inflammatory factors; HMGB1, paraoxonase-1, and macrophage migration inhibitory factor levels; erythrocyte sedimentation rate; platelet aggregation rate; and plasma viscosity of the observation group were better than those of the control group.

Research conclusions

Sodium ozagrel with atorvastatin can reduce inflammatory reactions.

Research perspectives

The results need to be verified with further larger scale studies and include other statins in combination with ozagrel.